Browse drugs

… the incidence and severity of irAEs in melanoma patients using nivolumab, along with the management and outcomes of irAEs, and the overa…

…nificant difference in mean bodyweight was found between groups.Nivolumab was administered to 108 patients: 64 (weight 62.29 ± 32.06kg) r…

…ortal outcome) as a suspected ADR of different ICIs (nivolumab, pembrolizumab and nivolumab+ipilimumab) within 2 months in the regional Pharm…

…een 1L and second-line (2L) therapies) was twice as long versus sunitinib. TFS and survival states for ICI plus vascular endothelial grow…

…demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clini…

…mab in safety run-in cohorts, 26 patients received rhIL-15 with nivolumab plus ipilimumab. The most common cancer types were gastrointest…

…9 life years; 95% CI 7929 to 8220; 10.8%; figure 4). The use of nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung c…

… genomic profiling will be presented at the meeting.Conclusions Nivolumab demonstrated a high rate of clinical complete responses in pati…

…unother Cancer. 2019;7:214.Wong MK, Milhem MM, Sacco JJ, et al. RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (…

…en of nausea and vomiting was reported in patients treated with ipilimumab. 55From patient selection to TIL expansion: a comprehensive ove…

…everity, and management of irAEs in melanoma patients receiving ipilimumab–nivolumab therapy.Material and Methods A retrospective observat…

…TEZO, atezolizumab; BINI, binimetinib; COBI, cobimetinib; ENCO, encorafenib; ESS, effective sample size; DAB, dabrafenib; NIVO, nivolumab; …